525 related articles for article (PubMed ID: 22152751)
1. Lapatinib and trastuzumab in combination with an aromatase inhibitor for the first-line treatment of metastatic hormone receptor-positive breast cancer which over-expresses human epidermal growth factor 2 (HER2): a systematic review and economic analysis.
Fleeman N; Bagust A; Boland A; Dickson R; Dundar Y; Moonan M; Oyee J; Blundell M; Davis H; Armstrong A; Thorp N
Health Technol Assess; 2011; 15(42):1-93, iii-iv. PubMed ID: 22152751
[TBL] [Abstract][Full Text] [Related]
2. Systematic review of lapatinib in combination with letrozole compared with other first-line treatments for hormone receptor positive(HR+) and HER2+ advanced or metastatic breast cancer(MBC).
Riemsma R; Forbes CA; Amonkar MM; Lykopoulos K; Diaz JR; Kleijnen J; Rea DW
Curr Med Res Opin; 2012 Aug; 28(8):1263-79. PubMed ID: 22738819
[TBL] [Abstract][Full Text] [Related]
3. Phase III, Randomized Study of Dual Human Epidermal Growth Factor Receptor 2 (HER2) Blockade With Lapatinib Plus Trastuzumab in Combination With an Aromatase Inhibitor in Postmenopausal Women With HER2-Positive, Hormone Receptor-Positive Metastatic Breast Cancer: Updated Results of ALTERNATIVE.
Johnston SRD; Hegg R; Im SA; Park IH; Burdaeva O; Kurteva G; Press MF; Tjulandin S; Iwata H; Simon SD; Kenny S; Sarp S; Izquierdo MA; Williams LS; Gradishar WJ
J Clin Oncol; 2021 Jan; 39(1):79-89. PubMed ID: 32822287
[TBL] [Abstract][Full Text] [Related]
4. Trastuzumab-containing regimens for metastatic breast cancer.
Balduzzi S; Mantarro S; Guarneri V; Tagliabue L; Pistotti V; Moja L; D'Amico R
Cochrane Database Syst Rev; 2014 Jun; 2014(6):CD006242. PubMed ID: 24919460
[TBL] [Abstract][Full Text] [Related]
5. Phase III, Randomized Study of Dual Human Epidermal Growth Factor Receptor 2 (HER2) Blockade With Lapatinib Plus Trastuzumab in Combination With an Aromatase Inhibitor in Postmenopausal Women With HER2-Positive, Hormone Receptor-Positive Metastatic Breast Cancer: ALTERNATIVE.
Johnston SRD; Hegg R; Im SA; Park IH; Burdaeva O; Kurteva G; Press MF; Tjulandin S; Iwata H; Simon SD; Kenny S; Sarp S; Izquierdo MA; Williams LS; Gradishar WJ
J Clin Oncol; 2018 Mar; 36(8):741-748. PubMed ID: 29244528
[TBL] [Abstract][Full Text] [Related]
6. Systemic therapy for patients with advanced human epidermal growth factor receptor 2-positive breast cancer: American Society of Clinical Oncology clinical practice guideline.
Giordano SH; Temin S; Kirshner JJ; Chandarlapaty S; Crews JR; Davidson NE; Esteva FJ; Gonzalez-Angulo AM; Krop I; Levinson J; Lin NU; Modi S; Patt DA; Perez EA; Perlmutter J; Ramakrishna N; Winer EP;
J Clin Oncol; 2014 Jul; 32(19):2078-99. PubMed ID: 24799465
[TBL] [Abstract][Full Text] [Related]
7. Prognostic Value of Intrinsic Subtypes in Hormone Receptor-Positive Metastatic Breast Cancer Treated With Letrozole With or Without Lapatinib.
Prat A; Cheang MC; Galván P; Nuciforo P; Paré L; Adamo B; Muñoz M; Viladot M; Press MF; Gagnon R; Ellis C; Johnston S
JAMA Oncol; 2016 Oct; 2(10):1287-1294. PubMed ID: 27281556
[TBL] [Abstract][Full Text] [Related]
8. Lapatinib combined with letrozole versus letrozole and placebo as first-line therapy for postmenopausal hormone receptor-positive metastatic breast cancer.
Johnston S; Pippen J; Pivot X; Lichinitser M; Sadeghi S; Dieras V; Gomez HL; Romieu G; Manikhas A; Kennedy MJ; Press MF; Maltzman J; Florance A; O'Rourke L; Oliva C; Stein S; Pegram M
J Clin Oncol; 2009 Nov; 27(33):5538-46. PubMed ID: 19786658
[TBL] [Abstract][Full Text] [Related]
9. Trastuzumab Emtansine for Treating HER2-Positive, Unresectable, Locally Advanced or Metastatic Breast Cancer After Treatment with Trastuzumab and a Taxane: An Evidence Review Group Perspective of a NICE Single Technology Appraisal.
Squires H; Stevenson M; Simpson E; Harvey R; Stevens J
Pharmacoeconomics; 2016 Jul; 34(7):673-80. PubMed ID: 26892972
[TBL] [Abstract][Full Text] [Related]
10. Hormonal therapies for early breast cancer: systematic review and economic evaluation.
Hind D; Ward S; De Nigris E; Simpson E; Carroll C; Wyld L
Health Technol Assess; 2007 Jul; 11(26):iii-iv, ix-xi, 1-134. PubMed ID: 17610808
[TBL] [Abstract][Full Text] [Related]
11. A global economic model to assess the cost-effectiveness of new treatments for advanced breast cancer in Canada.
Beauchemin C; Letarte N; Mathurin K; Yelle L; Lachaine J
J Med Econ; 2016 Jun; 19(6):619-29. PubMed ID: 26850287
[TBL] [Abstract][Full Text] [Related]
12. Cost-Effectiveness of Ribociclib plus Letrozole Versus Palbociclib plus Letrozole and Letrozole Monotherapy in the First-Line Treatment of Postmenopausal Women with HR+/HER2- Advanced or Metastatic Breast Cancer: A U.S. Payer Perspective.
Mistry R; May JR; Suri G; Young K; Brixner D; Oderda G; Biskupiak J; Tang D; Bhattacharyya S; Mishra D; Bhattacharyya D; Dalal AA
J Manag Care Spec Pharm; 2018 Jun; 24(6):514-523. PubMed ID: 29799329
[TBL] [Abstract][Full Text] [Related]
13. Quantitative ER and PgR assessment as predictors of benefit from lapatinib in postmenopausal women with hormone receptor-positive, HER2-negative metastatic breast cancer.
Finn RS; Press MF; Dering J; O'Rourke L; Florance A; Ellis C; Martin AM; Johnston S
Clin Cancer Res; 2014 Feb; 20(3):736-43. PubMed ID: 24198242
[TBL] [Abstract][Full Text] [Related]
14. Overall survival benefit with lapatinib in combination with trastuzumab for patients with human epidermal growth factor receptor 2-positive metastatic breast cancer: final results from the EGF104900 Study.
Blackwell KL; Burstein HJ; Storniolo AM; Rugo HS; Sledge G; Aktan G; Ellis C; Florance A; Vukelja S; Bischoff J; Baselga J; O'Shaughnessy J
J Clin Oncol; 2012 Jul; 30(21):2585-92. PubMed ID: 22689807
[TBL] [Abstract][Full Text] [Related]
15. Multicenter phase II study of neoadjuvant lapatinib and trastuzumab with hormonal therapy and without chemotherapy in patients with human epidermal growth factor receptor 2-overexpressing breast cancer: TBCRC 006.
Rimawi MF; Mayer IA; Forero A; Nanda R; Goetz MP; Rodriguez AA; Pavlick AC; Wang T; Hilsenbeck SG; Gutierrez C; Schiff R; Osborne CK; Chang JC
J Clin Oncol; 2013 May; 31(14):1726-31. PubMed ID: 23569315
[TBL] [Abstract][Full Text] [Related]
16. The efficacy of HER2-targeted agents in metastatic breast cancer: a meta-analysis.
Harris CA; Ward RL; Dobbins TA; Drew AK; Pearson S
Ann Oncol; 2011 Jun; 22(6):1308-1317. PubMed ID: 21119031
[TBL] [Abstract][Full Text] [Related]
17. Efficacy and safety of Trastuzumab added to standard treatments for HER2-positive metastatic breast cancer patients.
Zhu ZL; Zhang J; Chen ML; Li K
Asian Pac J Cancer Prev; 2013; 14(12):7111-6. PubMed ID: 24460260
[TBL] [Abstract][Full Text] [Related]
18. Combination of trastuzumab and letrozole after resistance to sequential trastuzumab and aromatase inhibitor monotherapies in patients with estrogen receptor-positive, HER-2-positive advanced breast cancer: a proof-of-concept trial (SAKK 23/03).
Koeberle D; Ruhstaller T; Jost L; Pagani O; Zaman K; von Moos R; Oehlschlegel C; Crowe S; Pilop C; Thuerlimann B;
Endocr Relat Cancer; 2011 Apr; 18(2):257-64. PubMed ID: 21317203
[TBL] [Abstract][Full Text] [Related]
19. Lapatinib: in postmenopausal women with hormone receptor-positive, HER2-positive metastatic breast cancer.
Curran MP
Drugs; 2010 Jul; 70(11):1411-22. PubMed ID: 20614948
[TBL] [Abstract][Full Text] [Related]
20. A systematic review of dual targeting in HER2-positive breast cancer.
Kümler I; Tuxen MK; Nielsen DL
Cancer Treat Rev; 2014 Mar; 40(2):259-70. PubMed ID: 24080156
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]